Compare Phillips 66 (PSX) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Phillips 66 vs Recursion Pharmaceuticals Inc — how do they compare? Phillips 66 trades at $261.37 (market cap $103.40B), while Recursion Pharmaceuticals Inc trades at $3.24 (market cap $1.86B). The key difference: Phillips 66 is far larger — about 55.6× Recursion Pharmaceuticals Inc's market cap, and Phillips 66 pays a 1.96% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| PSX | RXRX | |
|---|---|---|
Market Cap | $103.40B | $1.86B |
Sector | Energy | Health |
52-Week High | $260.78 | $6.79 |
52-Week Low | $126.76 | $2.84 |
Enterprise Value | $119.87B | $1.38B |
Dividend Yield | 1.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PSX trades at $259.14, up 1.59% today and near its 52-week high, supported by bullish technical signals and strong earnings beats in recent quarters. The stock shows robust profitability with a 24.02% ROE and attractive valuation metrics, including a P/E of 14.79. Recent news highlights momentum from high gas prices and refining efficiency gains, with a dividend of $1.27 payable in September 2026.
Outlook remains positive due to earnings momentum and sector tailwinds, but risks include volatile energy markets and declining revenue trends. Analysts are predominantly bullish with a $242.45 consensus target, though the current price exceeds this, suggesting near-term caution. Institutional buying and stable cash flow growth support long-term potential.
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
